Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
HHS-NIH11 Forecasted RFA-CA-26-001Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the feasibility of the proposed method, tool, assay, platform, or instrument. Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Funding Details
- Award Floor
- $50,000.00
- Award Ceiling
- $150,000.00
- Total Estimated Funding
- $4,700,000.00
- Expected Awards
- 17
Key Dates
- Posted
- September 8, 2025
- Closes
- N/A
- Archive Date
- N/A
Agency Information
- Agency Name
- HHS-NIH11
- Agency Code
- HHS-NIH11
- Funding Instrument
- Other